The Effectiveness of Two COX-2 Inhibitors in the Prophylaxis Against Heterotopic New Bone Formation: An Experimental Study in Rabbits

Journal of Surgical Research

Volumn 151, Issue 1, 2009, Pages 108-114

  Tsailas, Panagiotis G ^a   Babis, George C ^a   Nikolopoulos, Konstantinos ^a   Soucacos, Panayotis N ^a   Korres, Dimitrios S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

heterotopic ossification; meloxicam; nonsteroidal anti inflammatory drugs; parecoxib

Indexed keywords

INDOMETACIN; MELOXICAM; PARECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE RADIOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; HETEROTOPIC OSSIFICATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RANGE OF MOTION;

ANIMALS; BONE AND BONES; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; INDOMETHACIN; INJECTIONS, SUBCUTANEOUS; ISOXAZOLES; MALE; OSSIFICATION, HETEROTOPIC; OSTEOGENESIS; RABBITS; THIAZINES; THIAZOLES;

EID: 57149098092     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.12.804     Document Type: Article

References (51)

1. DeLee J., Ferrari A., and Charnley J. Ectopic bone formation following low friction arthroplasty of the hip. Clin Orthop Relat Res 121 (1976) 53
2. Ritter M.A., and Vaughan R.B. Ectopic ossification after total hip arthroplasty. Predisposing factors, frequency, and effect on results. J Bone Joint Surg Am 59 (1977) 345
3. Brooker A.F., Bowerman J.W., Robinson R.A., et al. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 55 (1973) 1629
4. Bosse M.J., Poka A., Reinert C.M., et al. Heterotopic ossification as a complication of acetabular fracture. Prophylaxis with low-dose irradiation. J Bone Joint Surg Am 70 (1988) 1231
5. Moed B.R., and Maxey J.W. The effect of indomethacin on heterotopic ossification following acetabular fracture surgery. J Orthop Trauma 7 (1993) 33
6. Garland D.E., Blum C.E., and Waters R.L. Periarticular heterotopic ossification in head-injured adults. Incidence and location. J Bone Joint Surg Am 62 (1980) 1143
7. Stover S.L., Niemann K.M., and Tulloss J.R. Experience with surgical resection of heterotopic bone in spinal cord injury patients. Clin Orthop Relat Res 263 (1991) 71
8. Coventry M.B., and Scanlon P.W. The use of radiation to discourage ectopic bone. A nine-year study in surgery about the hip. J Bone Joint Surg Am 63 (1981) 201
9. Fransen M., and Neal B. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 3 (2004) CD001160
10. Seegenschmiedt M.H., Martus P., Goldmann A.R., et al. Preoperative versus postoperative radiotherapy for prevention of heterotopic ossification (HO): First results of a randomized trial in high-risk patients. Int J Radiat Oncol Biol Phys 30 (1994) 63
11. Ritter M.A., and Gioe T.J. The effect of indomethacin on para-articular ectopic ossification following total hip arthroplasty. Clin Orthop Relat Res 167 (1982) 113
12. Romano C.L., Duci D., Romano D., et al. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty 19 (2004) 14
13. Bombardier C., Laine L., Reicin A., et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520
14. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247
15. Mamdani M., Rochon P.A., Juurlink D.N., et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325 (2002) 624
16. Reuben S.S. Considerations in the use of COX-2 inhibitors in spinal fusion surgery. Anesth Analg 93 (2001) 803
17. Reuben S.S. Effect of nonsteroidal anti-inflammatory drugs on osteogenesis and spinal fusion. Reg Anesth Pain Med 26 (2001) 590
18. Barthel T., Baumann B., Noth U., et al. Prophylaxis of heterotopic ossification after total hip arthroplasty: A prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand 73 (2002) 611
19. Legenstein R., Bosch P., and Ungersbock A. Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg 123 (2003) 91
20. Zacher J, Walther E, Gursche A. Prevention of periarticular ossification (PAO) after total hip replacement (THR) with rofecoxib 25 mg. Presented at the 2nd Annual European Congress of Rheumatology EULAR, Prague, Chech Republic, 2001.
21. Vastel L., Rosencher N., Siney H., et al. Prevention of heterotopic ossifications in hip arthroplasty: Effectiveness of selective Cox-2 inhibitors (celecoxib) versus ketoprofen. Rev Chir Orthop Reparatrice Appar Mot 91 (2005) 64
22. Banovac K., Williams J.M., Patrick L.D., et al. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord 42 (2004) 707
23. Michelsson J.E., Granroth G., and Andersson L.C. Myositis ossificans following forcible manipulation of the leg. A rabbit model for the study of heterotopic bone formation. J Bone Joint Surg Am 62 (1980) 811
24. Scott AC, Wong S, Ang K, et al. The relative effects of indomethacin, diphosphonates and low dose radiation for the prevention of heterotopic ossification. Presented at the 33rd annual meeting of the Orthopaedic Research Society, San Francisco, CA, January 1987.
25. Michelsson J.E., and Rauschning W. Pathogenesis of experimental heterotopic bone formation following temporary forcible exercising of immobilized limbs. Clin Orthop Relat Res 176 (1983) 265
26. Moed B.R., Resnick R.B., Fakhouri A.J., et al. Effect of two nonsteroidal antiinflammatory drugs on heterotopic bone formation in a rabbit model. J Arthroplasty 9 (1994) 81
27. Hierton C. Regional blood flow in experimental myositis ossificans. A microsphere study in conscious rabbits. Acta Orthop Scand 54 (1983) 58
28. Aho H.J., Aro H., Juntunen S., et al. Bone formation in experimental myositis ossificans. Light and electron microscopy study. APMIS 96 (1988) 933
29. Michelsson J.E., Pettilä M., Valtakari T., et al. Isolation of bone from muscles prevents the development of experimental callus-like heterotopic bone. A study of the interaction of bone and muscle in new bone formation. Clin Orthop Relat Res 302 (1994) 266
30. Aro H.T., Viljanto J., Aho H.J., et al. Macrophages in trauma-induced myositis ossificans. APMIS 99 (1991) 482
31. Onoe Y., Miyaura C., Kaminakayashiki T., et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 156 (1996) 758
32. Raisz L.G. Prostaglandins and bone: Physiology and pathophysiology. Osteoarthritis Cartilage 7 (1999) 419
33. Pilbeam C.C., Fall P.M., Alander C.B., et al. Differential effects of nonsteroidal anti-inflammatory drugs on constitutive and inducible prostaglandin G/H synthase in cultured bone cells. J Bone Miner Res 12 (1997) 1198
34. Spalding W.M., Reeves M.J., and Whelton A. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. Am J Ther 14 (2007) 3
35. Solomon D.H., Schneeweiss S., Glynn R.J., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109 (2004) 2068
36. Solomon D.H., Avorn J., Stürmer T., et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. Arthritis Rheum 54 (2006) 1378
37. White W.B., West C.R., Borer J.S., et al. Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized clinical trials. Am J Cardiol 99 (2007) 91
38. Curtis S.P., Ko A.T., Bolognese J.A., et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin 22 (2006) 2365
39. Motsko S.P., Rascati K.L., Busti A.J., et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 29 (2006) 621
40. Shaya F.T., Blume S.W., Blanchette C.M., et al. Selective cyclooxygenase-2 inhibition and cardiovascular effects: An observational study of a Medicaid population. Arch Intern Med 165 (2005) 181
41. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomised trials. BMJ 332 (2006) 1302
42. Valat J.P., Deray G., and Héloire F. Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?. Presse Med 35 (2006) 1S25
43. Hawkey C.J., Hawkey G.M., Everitt S., et al. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 61 (2006) 730
44. Chan A.T., Manson J.E., Albert C.M., et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578
45. White W.B., Strand V., Roberts R., et al. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 11 (2004) 244
46. Ott E., Nussmeier N.A., Duke P.C., et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125 (2003) 1481
47. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081
48. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology 104 (2006) 518
49. Chen L.C., and Ashcroft D.M. Do selective COX-2 inhibitors increase the risk of cerebrovascular events?. A meta-analysis of randomized controlled trials. J Clin Pharm Ther 31 (2006) 565
50. Gislason G.H., Jacobsen S., Rasmussen J.N., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113 (2006) 2906
51. Goldstein J.L., Aisenberg J., Lanza F., et al. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. Clin Ther 28 (2006) 340